Replies to post #373647 on Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Study just says in addition to SoC.

https://clinicaltrials.gov/ct2/show/study/NCT04784897?term=Brilacidin&draw=2&rank=2

Treatment period (Day 1-3 with potential to expand to Day 4-5): Randomized subjects will receive blinded study treatment once daily for 3 days by IV infusion, in addition to SoC.

Message in reply to:
Minnie, isn't P2 designed so that B is compared to the FDA designated SOC?

[frenchbroad]

In the USA yes Biopa. The standard of care is probably different however in Russia, not the land of the USA FDA. The standard of care is maybe even different from one trial location to another. This is also possible in the USA.

For me I like that Brilacidin has the chance to be tested against different standards of care. Let's see soon what it can do.